CN101972255A - 一种含盐酸罗格列酮药物组合物及其制备方法 - Google Patents
一种含盐酸罗格列酮药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN101972255A CN101972255A CN 201010520450 CN201010520450A CN101972255A CN 101972255 A CN101972255 A CN 101972255A CN 201010520450 CN201010520450 CN 201010520450 CN 201010520450 A CN201010520450 A CN 201010520450A CN 101972255 A CN101972255 A CN 101972255A
- Authority
- CN
- China
- Prior art keywords
- ketone hydrochloride
- lactose
- starch
- luogelie ketone
- magnesium stearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960004586 rosiglitazone Drugs 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 39
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 36
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 21
- 239000008101 lactose Substances 0.000 claims abstract description 21
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 20
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 20
- 229950005770 hyprolose Drugs 0.000 claims abstract description 20
- 229920002472 Starch Polymers 0.000 claims abstract description 19
- 235000019698 starch Nutrition 0.000 claims abstract description 19
- 239000008107 starch Substances 0.000 claims abstract description 19
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 18
- 239000008187 granular material Substances 0.000 claims abstract description 17
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 7
- -1 ketone hydrochloride Chemical class 0.000 claims description 29
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 17
- 238000005303 weighing Methods 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000011230 binding agent Substances 0.000 claims description 11
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 238000009501 film coating Methods 0.000 claims description 7
- 239000007888 film coating Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000004677 Nylon Substances 0.000 claims description 4
- 229920001778 nylon Polymers 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000010409 thin film Substances 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 4
- 239000000853 adhesive Substances 0.000 abstract 3
- 230000001070 adhesive effect Effects 0.000 abstract 3
- 238000005516 engineering process Methods 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 231100000963 pancreotoxicity Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105204505A CN101972255B (zh) | 2010-10-26 | 2010-10-26 | 一种含盐酸罗格列酮药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010105204505A CN101972255B (zh) | 2010-10-26 | 2010-10-26 | 一种含盐酸罗格列酮药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101972255A true CN101972255A (zh) | 2011-02-16 |
CN101972255B CN101972255B (zh) | 2012-06-27 |
Family
ID=43572185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010105204505A Active CN101972255B (zh) | 2010-10-26 | 2010-10-26 | 一种含盐酸罗格列酮药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101972255B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102389427A (zh) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | 含有罗格列酮和盐酸西替利嗪的固体口服制剂 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110934842A (zh) * | 2019-11-26 | 2020-03-31 | 卓和药业集团有限公司 | 盐酸地芬尼多片的制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1277965A (zh) * | 2000-06-14 | 2000-12-27 | 中国医药研究开发中心 | 盐酸罗格列酮及其应用 |
US20050163837A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone formulations |
CN101167726A (zh) * | 2007-10-16 | 2008-04-30 | 宁夏康亚药业有限公司 | 马来酸罗格列酮分散片及其制备方法 |
-
2010
- 2010-10-26 CN CN2010105204505A patent/CN101972255B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1277965A (zh) * | 2000-06-14 | 2000-12-27 | 中国医药研究开发中心 | 盐酸罗格列酮及其应用 |
US20050163837A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone formulations |
CN101167726A (zh) * | 2007-10-16 | 2008-04-30 | 宁夏康亚药业有限公司 | 马来酸罗格列酮分散片及其制备方法 |
Non-Patent Citations (1)
Title |
---|
《中国现代药物应用》 20090731 洪志慧等 盐酸罗格列酮口腔崩解片的研制 第3卷, 第14期 2 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102389427A (zh) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | 含有罗格列酮和盐酸西替利嗪的固体口服制剂 |
Also Published As
Publication number | Publication date |
---|---|
CN101972255B (zh) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2586464B1 (en) | Tolvaptan solid dispersion and its preparation method | |
CN103751193A (zh) | 包含利拉列汀和任选的sglt2抑制剂的药物组合物及其用途 | |
US20220249491A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
CN106924208A (zh) | 一种复方达格列净二甲双胍缓释片及其制备方法 | |
CN1762357B (zh) | 一种莫西沙星口服药物制剂及其制备方法 | |
CN100488515C (zh) | 一种地红霉素肠溶微丸及制备方法 | |
CN107281149A (zh) | 吲哚布芬药物组合物及其质控方法 | |
CN107432869A (zh) | 包含盐酸二甲双胍和恩格列净的双层片及其制备方法 | |
CN101972255B (zh) | 一种含盐酸罗格列酮药物组合物及其制备方法 | |
CN112933061B (zh) | 一种盐酸阿比多尔胶囊及其制备方法 | |
CN103271890B (zh) | 盐酸普拉克索胶囊及其制备方法 | |
CN102302466A (zh) | 一种可粉末直接压片的卡培他滨药用组合物及其应用 | |
CN101947219B (zh) | 一种复方替米沙坦苯磺酸氨氯地平药物组合物及其制备方法 | |
JP2022544167A (ja) | ニトロキソリンを含む医薬組成物、ニトロキソリン経口固形錠剤、その調製方法、及びその使用 | |
CN105412027A (zh) | 一种盐酸决奈达隆片剂的制备方法 | |
CN100421662C (zh) | 托拉塞米分散片及其制备方法和应用 | |
CN103405394A (zh) | 一种酒石酸美托洛尔缓释片及其制备方法 | |
CN102357093A (zh) | 一种甲磺酸阿比朵尔口服固体制剂的药物组合物 | |
CN102240271A (zh) | 盐酸乐卡地平分散片及其制备方法 | |
CN102144984A (zh) | 一种易于溶出的拉米夫定片及其制备方法 | |
CN103505466B (zh) | 含有盐酸二甲双胍与格列美脲的固体复方制剂及其制备方法和用途 | |
CN101836981B (zh) | 复方缬沙坦苯磺酸氨氯地平药物组合物及其制备方法 | |
CN101721414B (zh) | 含有盐酸吡格列酮和盐酸二甲双胍的组合物及其制备 | |
CN102552920B (zh) | 一种含恩替卡韦的药物组合物及其制备方法 | |
CN101491523A (zh) | 含微粉化格列喹酮的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: ZHEJIANG WANSHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: WANMA PHARMACEUTICAL CO., LTD., ZHEJIANG |
|
CP03 | Change of name, title or address |
Address after: 310011, No. 1, Wang Shan Road, Qingshan Lake Street, Ling'an City, Zhejiang, Hangzhou Patentee after: ZHEJIANG WANSHENG PHARMACEUTICAL Co.,Ltd. Address before: Hangzhou City, Zhejiang province 310011 Moganshan Road No. 989 Patentee before: ZHEJIANG WANMA PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: 310011 No.1 Wangjiashan Road, Qingshanhu Street, Lin'an City, Hangzhou City, Zhejiang Province Patentee after: Zhejiang Sansheng Mandi Pharmaceutical Co.,Ltd. Country or region after: China Address before: 310011 No.1 Wangjiashan Road, Qingshanhu Street, Lin'an City, Hangzhou City, Zhejiang Province Patentee before: ZHEJIANG WANSHENG PHARMACEUTICAL Co.,Ltd. Country or region before: China |
|
CP03 | Change of name, title or address |